Despite significant declines over the past 2 decades, the United States continues to experience birth rates among teenagers that are significantly higher than other high-income nations. Use of emergency contraception (EC) within 120 hours after unprotected or underprotected intercourse can reduce the risk of pregnancy. Emergency contraceptive methods include oral medications labeled and dedicated for use as EC by the US Food and Drug Administration (ulipristal and levonorgestrel), the “off-label” use of combined oral contraceptives, and insertion of a copper intrauterine device. Indications for the use of EC include intercourse without use of contraception; condom breakage or slippage; missed or late doses of contraceptives, including the oral contraceptive pill, contraceptive patch, contraceptive ring, and injectable contraception; vomiting after use of oral contraceptives; and sexual assault. Our aim in this updated policy statement is to (1) educate pediatricians and other physicians on available emergency contraceptive methods; (2) provide current data on the safety, efficacy, and use of EC in teenagers; and (3) encourage routine counseling and advance EC prescription as 1 public health strategy to reduce teenaged pregnancy.

Emergency contraception (EC) refers to methods of contraception that are used after sexual intercourse to reduce the risk of pregnancy. Methods currently available in the United States are (1) ulipristal acetate (UPA), an oral progesterone receptor agonist-antagonist; (2) levonorgestrel (LNG), an oral progestin; (3) the copper intrauterine device (Cu-IUD); and (4) off-label use of combined oral contraceptives (Yuzpe method). EC can reduce the risk of pregnancy if used up to 120 hours after unprotected intercourse, and hormonal emergency contraceptive pills (ECPs) are more likely to be effective the sooner they are used.1  Use of EC after unprotected or underprotected intercourse remains an important strategy to reduce unintended pregnancies among adolescents and women.

By the age of 19 years, approximately two-thirds of youth will have initiated sexual intercourse.2  Most teenagers report first intercourse with a steady partner and consensual sex.3  Approximately 11% of US high school students report experiencing a forced sexual experience ranging from kissing to forced intercourse.4  Sexual assault is 1 factor associated with risk for unintended pregnancy among adolescents.5  Youth with developmental and other disabilities may be at even higher risk of experiencing sexual abuse or assault than their peers are.6,7  Improved use of contraception, not declines in sexual activity, has been the most significant contributor to the decline in pregnancy risk among US teenagers over the past decade.8  Pediatricians have an important role to play in enabling adolescent access to all available contraceptive methods to address the Healthy People 2020 objective of continuing to reduce adolescent pregnancy in the United States.9

The most commonly used methods of contraception reported by teenagers who have had intercourse in the United States are the condom, followed by withdrawal, the oral contraceptive pill, and ECPs.2  Condoms are important for protection against sexually transmitted infections (STIs) as well as pregnancy, and the oral contraceptive pill can be an effective method for pregnancy prevention; however, both methods require strict adherence by the user to be maximally effective. Withdrawal is not recommended because of its relatively low effectiveness for pregnancy prevention and because it provides no protection against STIs. Although the American Academy of Pediatrics (AAP) and other medical organizations recommend the use of intrauterine devices (IUDs) and implants as the most effective methods for adolescents,10,11  rates of use of these methods remain low. The most recent analysis from the Centers for Disease Control and Prevention (CDC) indicates that only 3% of 15- to 19-year-olds who have ever had sex have used an IUD, and 3% report ever having used an implant.12

EC is the only contraceptive method designed to prevent pregnancy after intercourse. Indications for the use of EC include intercourse without use of contraception; condom breakage or slippage; missed or late doses of contraceptives, including the oral contraceptive pill, contraceptive patch, contraceptive ring, and injectable contraception; vomiting after use of oral contraceptive pills, and sexual assault. ECPs include products labeled and approved by the US Food and Drug Administration (FDA) for use as EC (levonorgestrel and UPA) and the off-label use of combination oral contraceptives (the Yuzpe method) that have been described in the literature since 1974.13  Insertion of a Cu-IUD within 5 days of unprotected intercourse is an additional method of EC available in the United States. Insertion of a Cu-IUD is the most effective method of EC and has the extra benefit of providing ongoing contraception when left in place.1

Studies have shown that adolescents are more likely to use ECPs when they have been supplied or prescribed in advance of need.14  As of August 2013, levonorgestrel EC is approved for over-the-counter sale throughout the United States to people of all ages15 ; however, barriers to access include cost and availability in pharmacies.16  Surveys suggest that most practicing pediatricians and pediatric residents do not routinely counsel patients about EC and do not prescribe it.1721  This policy statement provides updated guidance on all methods of EC available to US adolescents (Table 1) and ongoing policy and access issues.

TABLE 1

Selected Regimens for EC Available in the United States

BrandFirst DoseSecond Dose, 12 h LaterEthinyl Estradiol per Dose, μgLevonorgestrel per Dose, mg
Progestin-only pills
Next Choice or Plan B 2 pills None 1.5
Plan B One Step 1 pill None 1.5
Ovrette 20 pills 20 pills 0.75
Other ECP: ella 30 mg of UPA — — —
IUD: Paragard Insert within 120 h of unprotected intercourse Insert within 120 h of unprotected intercourse NA NA
Combined estrogen and progestin pills
Ovral 2 white pills 2 white pills 100 0.5
Levora 4 white pills 4 white pills 120 0.6
Nordette 4 light-orange pills 4 light-orange pills 120 0.6
Seasonale 4 pink pills 4 pink pills 120 0.6
Triphasil 4 yellow pills 4 yellow pills 120 0.5
Alesse 5 pink pills 5 pink pills 120 0.5
BrandFirst DoseSecond Dose, 12 h LaterEthinyl Estradiol per Dose, μgLevonorgestrel per Dose, mg
Progestin-only pills
Next Choice or Plan B 2 pills None 1.5
Plan B One Step 1 pill None 1.5
Ovrette 20 pills 20 pills 0.75
Other ECP: ella 30 mg of UPA — — —
IUD: Paragard Insert within 120 h of unprotected intercourse Insert within 120 h of unprotected intercourse NA NA
Combined estrogen and progestin pills
Ovral 2 white pills 2 white pills 100 0.5
Levora 4 white pills 4 white pills 120 0.6
Nordette 4 light-orange pills 4 light-orange pills 120 0.6
Seasonale 4 pink pills 4 pink pills 120 0.6
Triphasil 4 yellow pills 4 yellow pills 120 0.5
Alesse 5 pink pills 5 pink pills 120 0.5

Additional combinations are available at https://ec.princeton.edu/questions/dose.html#dose. NA, not applicable.

#### UPA Progesterone Agonist-Antagonist

In August 2010, the FDA approved a progesterone agonist-antagonist, UPA, for use as an EC.22  UPA binds to the human progesterone receptor, thereby preventing the binding of progesterone, and inhibits ovulation. Ulipristal, sold under the brand name ella (Watson, Morristown, NJ), is a single pill containing 30 mg of UPA and is indicated for use up to 120 hours after unprotected intercourse. It is important for patients to be counseled that onset of menses after UPA use may be later than expected and a pregnancy test is indicated if the patient does not have a period within 3 weeks. UPA is currently available by prescription only, regardless of age, and many pharmacies do not have it in stock.

#### Progestin-Only Pills

Levonorgestrel EC was approved by the FDA in 1999 under the brand name Plan B and is currently marketed under several names, including Plan B One Step (Teva Women’s Health, Woodcliff Lake, NJ), Take Action (Teva Women’s Health), Next Choice One Dose (Actavis Pharma, Inc, Parsippany, NJ), and My Way (Gavis Pharmaceuticals, Somerset, NJ). Although levonorgestrel EC originally consisted of 2 pills, current regimens are packaged as a single pill with 1.5 mg of levonorgestrel. Package labeling indicates that levonorgestrel EC should be taken within 72 hours of unprotected intercourse; however, data support that use up to 120 hours after intercourse may prevent pregnancy.23,24  Adolescents should be instructed to take 1.5 mg of levonorgestrel as soon as possible and up to 120 hours after unprotected intercourse. Adolescents should be aware that the medicine is less likely to be effective when taken at 120 hours when compared with immediate use. No physical examination or pregnancy testing is required before use. Adolescents are advised to test for pregnancy (at home or in a clinic) if they do not have a period within 3 weeks of EC use. It is important for patients to know that levonorgestrel use may cause the next period to come sooner than expected.1  Because use of ECPs may result in a delay in ovulation, it is imperative to counsel patients to abstain from intercourse or use condoms for pregnancy prevention until the next menses.

#### Combined Hormonal Regimens (Yuzpe Method)

The use of combination oral contraceptives for EC is commonly referred to as the Yuzpe method.13  Used since 1974, its acceptability and efficacy were limited by adverse effects of nausea and vomiting. The Yuzpe method involves taking 2 doses of pills 12 hours apart, each containing a minimum of 100 µg of ethinyl estradiol and a minimum of 500 µg of levonorgestrel. Other pill formulations used for EC are included in Table 1. Similar information is available from the Office of Population Research at Princeton University, which maintains a comprehensive source of information on EC (http://ec.princeton.edu/). The availability of many combination oral contraceptives with norgestrel or levonorgestrel makes this alternative particularly helpful when there is no or limited access to an EC product. Although combination oral contraceptives have not been labeled specifically for EC, the CDC “Selected Practice Recommendations for Contraceptive Use” and professional organizations such as the American College of Obstetricians and Gynecologists acknowledge the use of combination oral contraceptives as safe and effective for EC.25,26

Studies have established that the insertion of a Cu-IUD within 5 days of unprotected or underprotected intercourse is the most effective method of EC.2729  It must be inserted by a trained provider. In comparison with ECPs, the effectiveness of the Cu-IUD for EC results from the copper component and is not believed to vary by time of insertion within 120 hours of unprotected or underprotected sex.

The mechanisms of action of hormonal IUDs differ from those of the Cu-IUD, and hormonal IUDs have not been approved for use as EC. One published study found that women presenting for EC who desired an IUD for contraception could be offered levonorgestrel ECPs and also have a hormonal IUD placed at the same visit for ongoing contraception.30

The effectiveness of oral EC depends on inhibiting ovulation and is affected by the timing of use within the menstrual cycle. A recently published meta-analysis of ECP trial data compared the effectiveness of EC methods. Pooled data from trials suggest that UPA resulted in fewer pregnancies than levonorgestrel did (relative risk, 0.59; 95% confidence interval, 0.35–0.99; 2 randomized controlled trials, n = 3448; I2 = 0%; high-quality evidence).1  Levonorgestrel also resulted in fewer pregnancies than the Yuzpe method did (relative risk, 0.57; 95% confidence interval, 0.39–0.84; 6 randomized controlled trials, n = 4750; I2 = 23%; high-quality evidence).1  It should be noted, however, that current CDC guidance does not indicate a preference for UPA over levonorgestrel regimens.

Two secondary analyses of ECP trial data identified that repeat unprotected intercourse in the same cycle was associated with EC failure.31,32  The delay of ovulation from ECPs highlights the need for abstinence or contraception after ECP use.

Efficacy of the Cu-IUD is not affected by body weight. CDC recommendations indicate that young women in need of EC who do not wish to use a Cu-IUD or who do not have access to IUD insertion should be offered ECPs regardless of their weight.

Although no clinical trials have specifically evaluated the impact of BMI on the effectiveness of oral EC, meta-analyses have suggested that both levonorgestrel and UPA may be less effective in adolescents and women who are overweight.3133  In response to these data and labeling changes to EC products in Europe, the FDA conducted its own review of the evidence and issued a statement in 2016 indicating that the data regarding BMI and the effectiveness of levonorgestrel EC are conflicting and made no labeling changes. The FDA stated that there are no safety concerns with the use of levonorgestrel EC in women with BMI greater than 25 or with body weight greater than 165 pounds and that the most important factor affecting the medication’s effectiveness is how quickly it is taken after unprotected or underprotected intercourse.34

The only contraindication for use of EC is known pregnancy. According to the CDC Medical Eligibility Criteria for Contraceptive Use, pregnancy is an absolute contraindication for insertion of a Cu-IUD (category 4).35  ECPs are not indicated for use in patients with documented or suspected pregnancy; however, according to CDC Medical Eligibility Criteria, no harms to the woman, pregnancy, or fetus of inadvertent ECP use during pregnancy are known to exist.35  Use of ECPs will not disrupt a pregnancy that is implanted in the uterus, and ECPs are not abortifacients. Years of use of hormonal contraceptives indicate that there is no risk of teratogenicity from use of levonorgestrel EC or the Yuzpe method. There have also been no reports of fetal malformations after the use of UPA. Finally, repeat use of ECPs should prompt discussion of more effective, ongoing contraception, but there is no specific limit on repeated use, including within the same cycle. As noted below, however, the use of hormonal contraceptives within 5 days of UPA may reduce the effectiveness of UPA.

The most common adverse effects reported by users of UPA include headache (18%), nausea (12%), and abdominal pain (12%).36  It is recommended to redose UPA if vomiting occurs within 3 hours of the initial dose. For clinicians who are providing this medication in a setting where the patient is discharged before 3 hours after the dose and without an ongoing relationship with the patient (ie, emergency departments or urgent care), it may be important to discuss provisions for repeat dosing with patients if indicated.

The most common adverse effect reported after use of levonorgestrel EC is heavier menstrual bleeding; spotting may also be reported.37  The rate of nausea and vomiting with levonorgestrel EC is approximately half that with the Yuzpe method, and the routine use of antiemetics is not indicated. If vomiting does occur within 3 hours of use, the dose should be taken again. Repeated use of levonorgestrel EC is associated with the same adverse effects as 1-time use. A Cochrane Review of the subject found no serious adverse effects in trials of repeated use.38

The most common adverse effects that occur during the first 24 to 48 hours of using estrogen-containing EC methods are nausea (∼50%) and vomiting (∼20%), which seem to be unaffected by food intake.3941  The severity and incidence of nausea and vomiting can be decreased significantly by using an antiemetic 1 hour before an estrogen-containing regimen. Antiemetics are ineffective if taken after nausea is already present.41  If vomiting occurs within 3 hours of a dose, the dose should be repeated. As with daily use of oral contraceptives, other adverse effects might include fatigue, breast tenderness, headache, abdominal pain, and dizziness. It should be noted that CDC Medical Eligibility Criteria indicate that benefits of estrogen-containing pills for EC generally outweigh the risks of use even in adolescents or women with health conditions, such as thromboembolic disease (ie, category 2).35

The Cu-IUD can be inserted within 5 days of the first act of unprotected sexual intercourse as EC. Otherwise, eligibility criteria and initiation procedures for the Cu-IUD are the same for emergency or nonemergency Cu-IUD insertion. Pain with insertion is possible with use of the Cu-IUD for EC, and some patients may be fearful of pain and/or the required pelvic examination. Events associated with ongoing use of the Cu-IUD include expulsion (∼6% in first year) and heavy menstrual bleeding and/or painful periods (∼12%). Contraindications for Cu-IUD use include anatomic features that prevent insertion, Wilson disease, and signs of active cervical and/or pelvic infection.35  Of note, negative STI test results are not required before the insertion of an IUD. However, if an adolescent has not been screened for gonorrhea and Chlamydia according to screening guidelines,42  screening can be performed at the time of IUD insertion, and IUD insertion should not be delayed. The American College of Obstetricians and Gynecologists Long-Acting Reversible Contraception Program provides links to resources for clinicians who are interested in obtaining training on IUD insertion (www.acog.org/About-ACOG/ACOG-Departments/Long-Acting-Reversible-Contraception).

Although there is no specific contraindication for repeated use of EC, it should be emphasized to patients that ECPs are intended for emergency use and routine use of ECPs to prevent pregnancy is not as effective as the regular use of other forms of contraception. Ongoing hormonal contraceptives may be initiated or resumed immediately after use of levonorgestrel ECPs or the Yuzpe method; however, condoms or abstinence should be used in addition for 7 days for back-up protection.25  Initiation of ongoing hormonal contraceptives after the use of UPA should be delayed for 5 days to minimize the risk of interference with UPA activity.25  Prescriptions or a supply of hormonal contraceptives can be given at the time of UPA provision; however, patients should be instructed not to initiate them until 5 days after the dose of UPA. In addition, as with levonorgestrel or the Yuzpe method, patients should be counseled to abstain from intercourse or use condoms for 7 days after the initiation of ongoing contraception or until the start of their next period, whichever occurs first.25

The discussion of EC methods with patients must include the fact that none of these methods protect from STIs. Because of the cooccurring risk of STIs, offering STI testing at the visit for EC or encouraging patients to schedule follow-up visits for STI testing or treatment are advisable. In addition, follow-up visits are an important time to discuss options for ongoing contraception, abstinence, and consensual intercourse. Although EC is exclusively for use by individuals at risk of pregnancy, it is important for young men to be counseled on this method as well as on condom use and the regular use of other contraceptive methods so that they can communicate with their at-risk partners about optimal contraceptive use.

Data from the CDC indicate that the use of EC by female teenagers who had sexual intercourse at least once has increased over the past decade from 8% in 2002 to 22% in 2011 to 2013.2  This increase is likely related to regulatory changes that increased nonprescription access to levonorgestrel EC during this time. Despite the FDA approval of levonorgestrel for over-the-counter access without an age restriction, additional access barriers remain. In its most recent survey, the American Society for Emergency Contraception found that only 64% of pharmacies have ECPs in stock on their shelves, and among those that do, nearly half use a lock of some kind requiring employee assistance to obtain it from the shelf.16  Additionally, despite multiple brand-name and generic products on the market, the cost of levonorgestrel ECPs remains at $40 to$50, on average. This cost may be prohibitive, so pediatricians are encouraged to be aware of other resources for patients to obtain affordable ECPs, which may include college health services, school-based clinics, or Title X clinics. Insurance coverage may help with the cost barrier; however, coverage may vary by plan. In addition to the cost barrier, some stores also continue to enforce an unjustified age restriction on purchase.16

Access to UPA is also often limited. One study in Hawaii reported data from a secret-shopper study of pharmacies throughout the state that found that less than 3% had UPA in stock at the time of the request.43  The average cost of UPA in studied pharmacies was approximately \$50. Another study of pharmacy availability of UPA was conducted in Massachusetts and reported that 7% of pharmacies surveyed had UPA in stock.44

It is important that information about EC be included in all contraceptive and STI counseling for adolescents wherever these visits occur: the primary care office, the emergency department, specialty clinics, or inpatient units. Discussions should include indications for use and how patients can access EC in a timely fashion. Yet, provider communication about EC remains low and differs by patient characteristics. Findings from a nationally representative sample of sexually active 15- to 24-year-old women in the 2011–2015 National Survey of Family Growth found that provider communication about EC during a visit for a pelvic examination or Papanicolaou test was infrequent (19%) compared with communication about birth control (67%) and differed by patient characteristics, including race and/or ethnicity and insurance status.50  For example, a higher proportion of non-Hispanic black (25%) and Hispanic (27%) women reported receiving provider counseling about EC than did non-Hispanic white (14%) women. Reasons for differences in the reporting of counseling by race and/or ethnicity have not been identified by research to date. Adolescents with disabilities (both physical and cognitive) and their families should be counseled on EC as part of routine anticipatory guidance,51  especially because data suggest that children with disabilities have 2 times the risk of being sexual assaulted compared with children without disabilities.52  Offering advance prescription of ECPs is encouraged.

Laws allowing minors to consent to birth control services, including EC, without parents and rights to confidentiality vary by state. The Guttmacher Institute regularly updates information on the general categories of reproductive health services to which minors can consent by state.53  Minors in special circumstances, such as those in the foster care or juvenile justice systems, may face unique barriers to access and confidentiality.54  State laws regarding reporting age of consent for sexual activity and mandated reporting of sexual activity involving minors also vary by state.55

Despite the fact that hormonal EC will not disrupt an established pregnancy and studies showing that access to EC does not make it more likely that adolescents will engage in more sex or less likely that they will use condoms or other contraceptives,5658  public and medical discourse indicates that personal values of physicians and pharmacists continue to affect access to EC, particularly for adolescents.5963  Some physicians decline to provide EC to teenagers, regardless of the circumstance,20  and others may provide EC only if sexual assault has occurred.20,64  These decisions by physicians and pharmacists have important adverse consequences for adolescents in their ability to access EC.

A physician’s decision to provide EC at a time of need but not in advance of need may be related to the physician’s beliefs about whether it is acceptable for teenagers to have sex.20  Often, physicians hold conflicting values when approaching reproductive health issues with teenagers. Physicians may object to unprotected intercourse or intercourse outside of marriage, but they may also feel the need to prevent unwanted pregnancy among teenagers. It is important that pediatricians are aware of the ways in which the underlying beliefs they bring to their clinical practice affect the care that they provide.

The AAP has issued a policy statement on refusal to provide information or treatment on the basis of conscience, stating that pediatricians have a duty to inform their patients about relevant, legally available treatment options to which they object and have a moral obligation to refer patients to other physicians who will provide and educate about those services.65

Pediatricians may also encounter situations in which adolescents and their parents differ in their acceptance of sexual intercourse and contraception. Recognizing the importance of parents and families to adolescent health and helping adolescents make decisions with which they are comfortable can be challenging. In these cases, it is important for pediatricians to be knowledgeable about the rights of the adolescent with regard to consent for contraception in their state and ensure that adolescents are aware of these rights. Pediatricians can also be an important source of information for parents to help them communicate with their adolescents and to educate them about the importance of contraception and other prevention strategies to reduce risks associated with sexual activity if their adolescents make the decision to have sex.

We recommend the following.

1. Pediatricians should be aware that sexual behavior is prevalent among teenagers and that many sexually active teenagers may be the victims of sexual assault. Despite the availability of hormonal and long-acting contraceptives, the pregnancy prevention methods most commonly used by US teenagers are condoms and withdrawal. EC is an important back-up method to which all teenagers should have access.

2. Indications for use of EC include unprotected or underprotected intercourse, such as failure to use any form of contraception; sexual assault; and imperfect contraceptive use (eg, condom breakage or slippage and missed or late doses of oral contraceptive pills, contraceptive patch, contraceptive ring, or injectable contraception).

3. Pediatricians should provide ECPs (levonorgestrel or UPA) or Cu-IUD insertion to adolescents and young adults who are in immediate need of EC. In addition, the AAP recommends that pediatricians provide prescriptions and/or a supply of ECPs (with refills and condoms) so adolescents have them on hand in case of future need (ie, advanced provision). When a visit is not possible, ECPs can safely be prescribed over the phone without requiring a pregnancy test.

4. ECPs are most effective in decreasing risk of pregnancy when used as soon as possible, but may be used up to 120 hours after unprotected or underprotected intercourse. Adolescents should be instructed to use EC as soon as possible after unprotected intercourse and to then schedule a follow-up appointment with their primary provider to address the need for STI testing and ongoing contraception.

5. Advanced provision of ECPs increases the likelihood that teenagers will use EC when needed, reduces the time to use, and does not decrease condom or other contraceptive use. Levonorgestrel ECPs are available to male and female patients regardless of age without a prescription but may be expensive when purchased over the counter and are often covered by insurance with a prescription. UPA is available by prescription only. Pediatricians should be aware that the stock of available ECPs, especially UPA, may vary by pharmacy and that local patterns of availability, cost, insurance coverage, and sources of low-cost EC in their practice area may affect the ability of their patients to obtain recommended services.

6. When a dedicated ECP product or Cu-IUD are not options, the use of combined oral contraceptive pills for EC (Yuzpe method) may be recommended. Adverse effects may include nausea, vomiting, and abdominal pain, and coadministration of an antiemetic may be considered with this method.

7. Meta-analyses have suggested that both levonorgestrel and UPA may be less effective in individuals who are overweight. Efficacy of the Cu-IUD is not affected by weight. Patients who do not wish to use a Cu-IUD or do not have access to IUD insertion should be offered EC pills regardless of their weight.

8. Repeat episodes of unprotected sex during the same cycle after the use of ECPs increase the risk of pregnancy because they work by delaying ovulation. Adolescents who use ECPs should be counseled to abstain or use another method to prevent pregnancy until their next period. Ongoing hormonal contraceptives may be initiated immediately after the use of levonorgestrel ECPs or the Yuzpe method. Ongoing hormonal contraceptives should not be initiated sooner than 5 days after the use of UPA to minimize the risk of interference with UPA activity. Nonhormonal methods (eg, condoms) may be initiated immediately after ECP use.

Dr Upadhya was responsible for all aspects of revising and writing the policy statement with input from reviewers and the Board of Directors; she approves the final manuscript as submitted.

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Policy statements from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

FUNDING: No external funding.

• AAP

•
• CDC

Centers for Disease Control and Prevention

•
• Cu-IUD

copper intrauterine device

•
• EC

emergency contraception

•
• ECP

emergency contraceptive pill

•
• FDA

•
• IUD

intrauterine device

•
• STI

sexually transmitted infection

•
• UPA

ulipristal acetate

1
Shen
J
,
Che
Y
,
Showell
E
,
Chen
K
,
Cheng
L
.
Interventions for emergency contraception
.
Cochrane Database Syst Rev
.
2017
;
8
(
8
):
CD001324
2
Martinez
GM
,
Abma
JC
.
Sexual activity, contraceptive use, and childbearing of teenagers aged 15–19 in the United States
.
NCHS Data Brief
.
2015
;(
209
):
1
8
3
Martinez
G
,
Copen
CE
,
Abma
JC
.
Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006–2010 national survey of family growth
.
Vital Health Stat 23
.
2011
;(
31
):
1
35
4
Kann
L
,
McManus
T
,
Harris
WA
, et al
.
Youth risk behavior surveillance - United States, 2015
.
MMWR Surveill Summ
.
2016
;
65
(
6
):
1
174
5
Trent
M
,
Clum
G
,
Roche
KM
.
Sexual victimization and reproductive health outcomes in urban youth
.
Ambul Pediatr
.
2007
;
7
(
4
):
313
316
6
Helton
JJ
,
Gochez-Kerr
T
,
Gruber
E
.
Sexual abuse of children with learning disabilities
.
Child Maltreat
.
2018
;
23
(
2
):
157
165
7
Casteel
C
,
Martin
SL
,
Smith
JB
,
Gurka
KK
,
Kupper
LL
.
National study of physical and sexual assault among women with disabilities
.
Inj Prev
.
2008
;
14
(
2
):
87
90
8
Lindberg
L
,
Santelli
J
,
Desai
S
.
Understanding the decline in adolescent fertility in the United States, 2007–2012
.
.
2016
;
59
(
5
):
577
583
9
US Department of Health and Human Services
.
Healthy People 2020 objectives: family planning. Available at: https://www.healthypeople.gov/2020/topics-objectives/topic/family-planning/objectives. Accessed September 30, 2018
10
Ott
MA
,
Sucato
GS
;
.
.
Pediatrics
.
2014
;
134
(
4
). Available at: www.pediatrics.org/cgi/content/full/134/4/e1257
11
American College of Obstetricians and Gynecologists
.
ACOG Committee Opinion No. 735: adolescents and long-acting reversible contraception: implants and intrauterine devices
.
Obstet Gynecol
.
2018
;
131
(
5
):
e130
e139
12
Abma
JC
,
Martinez
GM
.
Sexual activity and contraceptive use among teenagers in the United States, 2011–2015
.
Natl Health Stat Rep
.
2017
;(
104
):
1
23
13
Yuzpe
AA
,
Thurlow
HJ
,
Ramzy
I
,
Leyshon
JI
.
Post coital contraception–A pilot study
.
J Reprod Med
.
1974
;
13
(
2
):
53
58
14
Meyer
JL
,
Gold
MA
,
Haggerty
CL
.
.
.
2011
;
24
(
1
):
2
9
15
Rowan
A.
Obama administration yields to the courts and the evidence, allows emergency contraception to be sold without restrictions.
Available at: https://www.guttmacher.org/gpr/2013/06/obama-administration-yields-courts-and-evidence-allows-emergency-contraception-be-sold. Accessed January 7, 2019
16
American Society for Emergency Contraception
.
Inching towards progress: ASEC’s 2015 pharmacy access study. Available at: http://americansocietyforec.org/uploads/3/4/5/6/34568220/asec_2015_ec_access_report_1.pdf. Accessed February 13, 2017
17
Sills
MR
,
Chamberlain
JM
,
Teach
SJ
.
The associations among pediatricians’ knowledge, attitudes, and practices regarding emergency contraception
.
Pediatrics
.
2000
;
105
(
4, pt 2
):
954
956
18
Golden
NH
,
Seigel
WM
,
Fisher
M
, et al
.
Emergency contraception: pediatricians’ knowledge, attitudes, and opinions
.
Pediatrics
.
2001
;
107
(
2
):
287
292
19
Lim
SW
,
Iheagwara
KN
,
Legano
L
,
Coupey
SM
.
Emergency contraception: are pediatric residents counseling and prescribing to teens?
.
2008
;
21
(
3
):
129
134
20
KK
,
Trent
ME
,
Ellen
JM
.
Impact of individual values on adherence to emergency contraception practice guidelines among pediatric residents: implications for training
.
.
2009
;
163
(
10
):
944
948
21
Batur
P
,
Cleland
K
,
McNamara
M
,
Wu
J
,
Pickle
S
;
EC Survey Group
.
Emergency contraception: a multispecialty survey of clinician knowledge and practices
.
Contraception
.
2016
;
93
(
2
):
145
152
22
Pharma
HRA
.
FDA advisory committee unanimously recommends approval of HRA pharma’s ulipristal acetate for emergency contraception
.
2010
.
Available at: https://ec.princeton.edu/news/HRA_Ella_PR.pdf. Accessed January 7, 2019
23
von Hertzen
H
,
Piaggio
G
,
Ding
J
, et al;
WHO Research Group on Post-ovulatory Methods of Fertility Regulation
.
Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial
.
Lancet
.
2002
;
360
(
9348
):
1803
1810
24
Rodrigues
I
,
Grou
F
,
Joly
J
.
Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse
.
Am J Obstet Gynecol
.
2001
;
184
(
4
):
531
537
25
Curtis
KM
,
Jatlaoui
TC
,
Tepper
NK
, et al
.
U.S. selected practice recommendations for contraceptive use, 2016
.
MMWR Recomm Rep
.
2016
;
65
(
4
):
1
66
26
American College of Obstetricians and Gynecologists
.
Practice Bulletin No. 152: emergency contraception
.
Obstet Gynecol
.
2015
;
126
(
3
):
e1
e11
27
Cleland
K
,
Zhu
H
,
Goldstuck
N
,
Cheng
L
,
Trussell
J
.
The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience
.
Hum Reprod
.
2012
;
27
(
7
):
1994
2000
28
Wu
S
,
Godfrey
EM
,
Wojdyla
D
, et al
.
Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial
.
BJOG
.
2010
;
117
(
10
):
1205
1210
29
Turok
DK
,
Godfrey
EM
,
Wojdyla
D
, et al
.
Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle
.
Hum Reprod
.
2013
;
28
(
10
):
2672
2676
30
Turok
DK
,
Sanders
JN
,
Thompson
IS
, et al
.
Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study
.
Contraception
.
2016
;
93
(
6
):
526
532
31
Moreau
C
,
Trussell
J
.
Results from pooled Phase III studies of ulipristal acetate for emergency contraception
.
Contraception
.
2012
;
86
(
6
):
673
680
32
Glasier
A
,
Cameron
ST
,
Blithe
D
, et al
.
Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel
.
Contraception
.
2011
;
84
(
4
):
363
367
33
Kapp
N
,
Abitbol
JL
,
Mathé
H
, et al
.
Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception
.
Contraception
.
2015
;
91
(
2
):
97
104
34
.
FDA communication on levonorgestrel emergency contraceptive effectiveness and weight
.
35
Curtis
KM
,
Tepper
NK
,
Jatlaoui
TC
, et al
.
US medical eligibility criteria for contraceptive use, 2016
.
MMWR Recomm Rep
.
2016
;
65
(
3
):
1
103
36
. Highlights of prescribing information: ella (ulipristal acetate) tablet. Revised March
2015
. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2015/022474s007lbl.pdf. Accessed January 3, 2019
37
. Highlights of prescribing information: Plan B One-Step tablet (levonorgestrel) 1.5mg for oral use. Revised July
2009
. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2009/021998lbl.pdf. Accessed January 3, 2019
38
Halpern
V
,
Raymond
EG
,
Lopez
LM
.
Repeated use of pre- and postcoital hormonal contraception for prevention of pregnancy
.
Cochrane Database Syst Rev
.
2010
;(
1
):
CD007595
39
Ellertson
C
,
Webb
A
,
Blanchard
K
, et al
.
Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial
.
Obstet Gynecol
.
2003
;
101
(
6
):
1160
1167
40
Percival-Smith
RK
,
Abercrombie
B
.
Postcoital contraception with dl-norgestrel/ethinyl estradiol combination: six years experience in a student medical clinic
.
Contraception
.
1987
;
36
(
3
):
287
293
41
Raymond
EG
,
Creinin
MD
,
Barnhart
KT
, et al
.
Meclizine for prevention of nausea associated with use of emergency contraceptive pills: a randomized trial
.
Obstet Gynecol
.
2000
;
95
(
2
):
271
277
42
Workowski
KA
,
Bolan
GA
;
Centers for Disease Control and Prevention
.
Sexually transmitted diseases treatment guidelines, 2015
.
MMWR Recomm Rep
.
2015
;
64
(
RR-03
):
1
137
43
Bullock
H
,
Steele
S
,
Kurata
N
, et al
.
Contraception
.
2016
;
93
(
5
):
452
454
44
Brant
A
,
White
K
,
St Marie
P
.
Pharmacy availability of ulipristal acetate emergency contraception: an audit study
.
Contraception
.
2014
;
90
(
3
):
338
339
45
.
Emergency contraception
.
Pediatrics
.
2012
;
130
(
6
):
1174
1182
46
Garbers
S
,
Bell
DL
,
Ogaye
K
,
Marcell
AV
,
Westhoff
CL
,
Rosenthal
SL
.
Advance provision of emergency contraception to young men: an exploratory study in a clinic setting [published online ahead of print April 17, 2018]
.
Contraception
.
doi:10.1016/j.contraception.2018.04.005
47
Marcell
AV
,
Waks
AB
,
Rutkow
L
, et al
.
What do we know about males and emergency contraception? A synthesis of the literature
.
Perspect Sex Reprod Health
.
2012
;
44
(
3
):
184
193
48
Schrager
SM
,
Olson
J
,
Beharry
M
, et al
.
Young men and the morning after: a missed opportunity for emergency contraception provision?
J Fam Plann Reprod Health Care
.
2015
;
41
(
1
):
33
37
49
Richards
MJ
,
Peters
M
,
Sheeder
J
,
Kaul
P
.
Contraception and adolescent males: an opportunity for providers
.
.
2016
;
58
(
3
):
366
368
50
Liddon
N
,
Steiner
RJ
,
Martinez
GM
.
Provider communication with adolescent and young females during sexual and reproductive health visits: findings from the 2011–2015 National Survey of Family Growth
.
Contraception
.
2018
;
97
(
1
):
22
28
51
Murphy
NA
,
Elias
ER
.
Sexuality of children and adolescents with developmental disabilities
.
Pediatrics
.
2006
;
118
(
1
):
398
403
52
Hibbard
RA
,
Desch
LW
;
American Academy of Pediatrics Committee on Child Abuse and Neglect
;
American Academy of Pediatrics Council on Children With Disabilities
.
Maltreatment of children with disabilities
.
Pediatrics
.
2007
;
119
(
5
):
1018
1025
53
Guttmacher Institute
.
.
2018
.
54
Dudley
TI
.
Bearing injustice: foster care, pregnancy prevention, and the law
.
Law Justice
.
2013
;
28
(
1
):
77
115
55
US Department of Health and Human Services
.
Statutory rape: a guide to state laws and reporting requirements
.
2004
.
56
Stewart
HE
,
Gold
MA
,
Parker
AM
.
The impact of using emergency contraception on reproductive health outcomes: a retrospective review in an urban adolescent clinic
.
.
2003
;
16
(
5
):
313
318
57
Gold
MA
,
Wolford
JE
,
Smith
KA
,
Parker
AM
.
The effects of advance provision of emergency contraception on adolescent women’s sexual and contraceptive behaviors
.
.
2004
;
17
(
2
):
87
96
58
Raine
TR
,
Harper
CC
,
Rocca
CH
, et al
.
Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial
.
JAMA
.
2005
;
293
(
1
):
54
62
59
Conard
LA
,
Fortenberry
JD
,
Blythe
MJ
,
Orr
DP
.
Pharmacists’ attitudes toward and practices with adolescents
.
.
2003
;
157
(
4
):
361
365
60
Grimes
DA
.
Emergency contraception: politics trumps science at the U.S. Food and Drug Administration
.
Obstet Gynecol
.
2004
;
104
(
2
):
220
221
61
Pruitt
SL
,
Mullen
PD
.
Contraception or abortion? Inaccurate descriptions of emergency contraception in newspaper articles, 1992-2002
.
Contraception
.
2005
;
71
(
1
):
14
21
62
Karasz
A
,
Kirchen
NT
,
Gold
M
.
The visit before the morning after: barriers to preprescribing emergency contraception
.
Ann Fam Med
.
2004
;
2
(
4
):
345
350
63
Fairhurst
K
,
Wyke
S
,
Ziebland
S
,
Seaman
P
,
Glasier
A
.
“Not that sort of practice”: the views and behaviour of primary care practitioners in a study of advance provision of emergency contraception
.
Fam Pract
.
2005
;
22
(
3
):
280
286
64
Miller
MK
,
Mollen
CJ
,
O’Malley
D
, et al
.
Providing adolescent sexual health care in the pediatric emergency department: views of health care providers
.
Pediatr Emerg Care
.
2014
;
30
(
2
):
84
90
65
Committee on Bioethics
.
Policy statement–Physician refusal to provide information or treatment on the basis of claims of conscience
.
Pediatrics
.
2009
;
124
(
6
):
1689
1693

Krishna K. Upadhya, MD, MPH, FAAP

Cora C. Breuner, MD, MPH, FAAP, Chairperson

Elizabeth M. Alderman, MD, FAAP, FSAHM

Laura K. Grubb, MD, FAAP

Laurie L. Hornberger, MD, MPH, FAAP

Makia E. Powers, MD, MPH, FAAP

Stephenie B. Wallace, MD, FAAP

Liwei L. Hua, MD, PhD – American Academy of Child and Adolescent Psychiatry

Margo Lane, MD – Canadian Pediatric Society

Meredith Loveless, MD – American College of Obstetricians and Gynecologists

Seema Menon, MD – North American Society of Pediatric and Adolescent Gynecology

Lauren B. Zapata, PhD, MSPH – Centers for Disease Control and Prevention

Karen Smith

James Baumberger, MPP

## Competing Interests

POTENTIAL CONFLICT OF INTEREST: The author has indicated she has no potential conflicts of interest to disclose.

FINANCIAL DISCLOSURE: The author has indicated she has no financial relationships relevant to this article to disclose.